Aerosol therapy in acute respiratory distress syndrome: from bench to bedside—drug evidence, delivery constraints, and a phenotype-informed translational framework
Acute respiratory distress syndrome (ARDS) is a heterogeneous form of acute lung injury characterized by alveolar-capillary barrier disruption, pulmonary edema, surfactant dysfunction and ventilation-perfusion mismatch. Lung-protective ventilation, appropriate positive end-expiratory pressure (PEEP), prone positioning when indicated, and treatment of the precipitating cause remain central to care. Aerosolized therapies are attractive because they may achieve local respiratory exposure, but the nominal dose loaded into a device is not equivalent to emitted dose, airway-delivered mass, regional deposition or biologically active target exposure. This narrative review examines aerosol therapy across drug biology, aerosol technology, respiratory-support configuration and ARDS phenotype. It summarizes evidence for inhaled pulmonary vasodilators, β2-agonists, nebulized heparin, inhaled corticosteroids, exogenous surfactant, inhaled antibiotics and secretion-directed therapies, while distinguishing gaseous inhaled nitric oxide (iNO) from particle-based aerosol delivery. iNO and inhaled prostacyclins may improve oxygenation in selected patients, but consistent patient-centred benefit has not been established; other aerosol strategies remain indication-specific or investigational. Device output, formulation, particle characteristics, circuit geometry, humidification, artificial airway, ventilator settings, interface leakage and regional aeration can alter exposure. Recent practice data demonstrate frequent aerosol use and suboptimal device positioning in some intensive care settings, but do not establish that positioning differences cause worse outcomes. We propose a phenotype-informed translational pathway linking biological target, patient characteristics, aerosol accessibility, drug-device selection, delivery fidelity, response assessment and stopping criteria. This framework is conceptual and requires prospective validation. Future studies should standardize exposure reporting, measure deposition where feasible, prespecify patient phenotypes and clinically meaningful outcomes, and preserve lung-protective care and safety.
Authors
- Srishankar Bairy (ORCID: https://orcid.org/0009-0006-3113-306X)
- Carishma Sheela
- Eldhos Jacob
Institutions
- Father Muller Medical College Hospital (IN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3389/fmed.2026.1969715
- Primary Topic
- Respiratory Support and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00